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Background: Levodopa-carbidopa intestinal gel (LCIG) provides continuous infusion and reduces “off”
time in advanced Parkinson's disease (PD) patients with motor ﬂuctuations despite optimized
pharmacotherapy.
Methods: Clinical experience with 2 LCIG dosing paradigms from phase 3 studies was examined. In an
open-label, 54-week study, LCIG was initiated as daytime monotherapy via nasojejunal (NJ) tube then
switched to percutaneous endoscopic gastrojejunostomy (PEG-J) tube; adjunctive therapy was permitted
28 days postPEG-J. In a 12-week, double-blind, placebo-controlled, double-dummy trial, patients
continued stable doses of existing anti-PD medications, but LCIG replaced daytime oral levodopa-
carbidopa and was initiated directly via PEG-J.
Results: In the open-label study, 92% of 354 patients received monotherapy at postePEG-J week 4; mean
titration duration was 7.6 days; dosing remained stable post-titration (mean total daily dose [TDD] was
1572 mg at last visit). In the double-blind trial, 84% received polypharmacy; mean titration took 7.1 days
for the LCIG arm (TDD post-titration: 1181 mg; n ¼ 37). At postePEG-J week 4, mean “off” time with LCIG
was reduced by 3.9 h (open-label/monotherapy study) and 3.7 h (double-blind/polypharmacy trial). NJ
treatment (open-label study only) required an additional procedure with related adverse events (AEs)
and withdrawals. The most common AEs during PEG-J weeks 1e4 in the open-label/monotherapy and
double-blind/polypharmacy trials, respectively, were complication of device insertion (35%, 57%) and
abdominal pain (26%, 51%). Discontinuations due to nonprocedure/nondevice AEs were low (2.2%, 2.7%).
Conclusion: These results support the option of initiating LCIG with or without NJ and as either mono-
therapy or polypharmacy.
© 2015 AbbVie Inc, employer of authors K. Chatamra, W. Robieson, and J. Benesh. Published by Elsevier
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Although levodopa has been established as the gold standardLos Angeles, CA 90033, USA.
).
Chatamra, W. Robieson, and J. Ben
d/4.0/).therapy for Parkinson's disease (PD) [1e5], disabling motor com-
plications emerge with ongoing oral levodopa treatment [2e7].
Levodopa-associated motor complications are thought to develop
at least in part due to pulsatile dopaminergic stimulation arising
from oral levodopa's short half-life and oral route of administration
[8e10]. In advanced PD patients, continuous drug delivery with
levodopa-carbidopa intestinal gel (LCIG) signiﬁcantly decreasedesh. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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release (LC-IR) tablets in randomized [11e13] and open-label
studies [14e19].
In countries where LCIG is currently approved, it is typically
initiated as monotherapy for advanced PD via a temporary naso-
jejunal (NJ) tube. However, prior LCIG studies have generally been
small, often retrospective, and provided limited information
regarding initiation and titration methodology [13,20,21]. We,
therefore, retrospectively examined clinical experiences with LCIG
initiation and titration, alongwith efﬁcacy and safety data, from the
recent phase 3 studies supporting United States registration, in
advanced PD.
One study was an international, open-label, long-term safety,
54-week study of LCIG ﬁrst as monotherapy via NJ tube followed by
percutaneous endoscopic gastrojejunostomy (PEG-J) tube in 354
patients [14,15]. The other registration study was a 12-week, ran-
domized, double-blind, double-dummy, pivotal trial, with direct-
to-PEG-J titration along with stable adjunctive therapy, in 71 pa-
tients [11]. These studies provided an opportunity to evaluate LCIG
initiation (1) as monotherapy or as adjunctive therapy (poly-
pharmacy), and (2) via NJ prior to PEG-J or directly via PEG-J.2. Methods
These studies of LCIG (levodopa 20 mg/mL, carbidopa mono-
hydrate 5 mg/mL) had similar eligibility criteria and safety and
efﬁcacy endpoints [11,14,15]. All patients had advanced, levodopa-
responsive PD with severe motor ﬂuctuations (3 h of “off” time/
day) despite optimized anti-PD pharmacotherapy. Patients were
titrated for dose optimization, maximizing functional “on” time
without troublesome dyskinesia (i.e. without dyskinesias that
interfere with function or cause meaningful discomfort) while
minimizing “off” episodes and troublesome dyskinesia. Initial
titration periods were up to 2 weeks; completion was deﬁned as 2
consecutive days with no dose adjustments. The key efﬁcacy
endpoint was change in “off” time from baseline assessed by pa-
tient diaries [22].
In both studies, after a 16-h daily infusion, the pump was
turned off at night and oral LC-IR was permitted. For this report,
“LCIG monotherapy” is deﬁned as LCIG alone during the 16-hFig. 1. Study designs: A. Open-label study. B. Double-blind study. *Sustained-release levod
carbidopa intestinal gel (LCIG); levodopa-carbidopa immediate release (LC-IR); nasojejunalinfusion day with or without LC-IR at night. Other levodopa for-
mulations and apomorphine were not permitted. Efﬁcacy and
safety analyses presented are per individual study protocol unless




Patients were to discontinue all adjunctive anti-PD medications
(e.g. dopamine agonists, amantadine, catechol-O-methyl trans-
ferase inhibitors) prior to receiving LCIG (Fig. 1A) [14,15]. LCIG was
initiated via a temporary NJ tube to conﬁrm levodopa response and
to optimize LCIG dosing before PEG-J placement. LCIG was titrated
as monotherapy (with only LC-IR tablets permitted at night). At the
investigator's discretion, adjunctive anti-PD medications could be
reinitiated after 28 days of treatment via PEG-J. Rescue medication,
if needed, was extra LCIG doses (or LC-IR if LCIG was interrupted).
2.1.2. Double-blind trial
LCIG infusion, initiated via PEG-J, plus placebo capsules was
compared with encapsulated LC-IR tablets plus placebo gel infusion
(Fig. 1B) [11]. LCIG/LC-IR was titrated during the ﬁrst 4 weeks, fol-
lowed by an 8-week treatment period with a stable regimen. All
concomitant anti-PD medications (except apomorphine/other
levodopa formulations) were continued and kept stable throughout
the 12-week study. Rescue medication, if needed, was open-label
LC-IR tablets.
2.2. LCIG titration schemes
2.2.1. Open-label study
The NJ and PEG-J titration phases each were to be completed
2e14 days. For the initial NJ phase, patients were hospitalized 14
days as needed for titration. The starting LCIG dose was calculated
from the total daily dose (TDD) of LC-IR taken the day before NJ
placement. The LCIG TDD consisted of individually adjusted
morning, continuous maintenance, and extra doses.
The initial morning dose was calculated as a proportion of the
patient's usual morning dose of oral levodopa (typically 60e80%,opa-carbidopa, other levodopa formulations, and apomorphine excluded. Levodopa-
(NJ); Parkinson's disease (PD); percutaneous endoscopic gastrojejunostomy (PEG-J).
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nance dose was 90% of the LC-IR TDD prior to LCIG treatment,
minus the morning dose, and administered over 16 h. Dosage was
adjusted per investigator discretion; patients were monitored
hourly for symptoms and dose adjustments. Extra doses to control
emergent symptoms were also individualized, with 20-mg incre-
mental change permitted. During titration, extra doses could be
self-administered every hour; post-titration only every 2 h. The
ﬁnal NJ dose was the initial PEG-J dose.2.2.2. Double-blind trial
The initial dosage was based on the LC-IR dosing established
during screening. To maintain the double-dummy blind, levodopa-
carbidopa dose adjustments were made only daily in the morning,
as previously described [11]. Both gel infusion and oral capsules
were simultaneously adjusted in matched, ﬁxed increments during
the titration period, with no change permitted during the mainte-
nance phase, and the pump was locked so patients could not
modify the dose. After the initial 2-week, in-hospital titration
period, additional adjustments were permitted during weeklyFig. 2. Mean levodopa dosages over time in patients receiving LCIG: A. Open-label
study. B. Double-blind study. Note: The mean ± SD total daily dose contribution
from LCIG is levodopa administered as a morning dose and a continuous maintenance
dose (plus, for the open-label study only, the extra LCIG doses that were permitted).
LC-IR was used at night when the pump was turned off and replacement in the event
infusion was disrupted. Panel A adapted from Fernandez HH, Standaert DG, Hauser RA,
Lang AE, Fung VSC, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced
Parkinson disease: ﬁnal 12-month, open-label results. Mov. Disord. 30 (2015)
500e509. Levodopa-carbidopa intestinal gel (LCIG); levodopa-carbidopa immediate
release (LC-IR); nasojejunal (NJ); percutaneous endoscopic gastrostomy (PEG).visits until week 4. Extra doses were not permitted, although oral
LC-IR as rescue medication was allowed.
3. Results
3.1. Titration, levodopa dosage, and adjunctive therapy
3.1.1. Open-label study
Of 354 enrolled patients, 80% were receiving adjunctive medi-
cations at screening along with a mean ± SD levodopa TDD of
1083 ± 582mg/day (Fig. 2A). For the 324 patients who proceeded to
the PEG-J phase, the mean ± SD time to LCIG dose optimizationwas
4.5 ± 2.1 days in the NJ period, 3.1 ± 2.7 days for ﬁne-tuning after
PEG-J placement, for a total of 7.6 ± 3.4 days. The mean levodopa
TDD of LCIG during the last NJ titration day was 1507 ± 570 mg,
similar to the 1532 ± 561 mg at the end of PEG-J titration, and
increased from screening for nearly all patients. Throughout the
study, the mean extra dose was 43 ± 20 mg of levodopa. Patients
self-administered a mean ± SD 2.9 ± 1.5 and 1.6 ± 1.2 extra doses/
day during the NJ and PEG-J titration periods, respectively. On pa-
tients' last titration day, which occurred before postePEG-J week 4,
mean total extra LCIG (levodopa) dose was 120 ± 120 mg (6 ± 6 mL
of LCIG; n ¼ 252).
The mean TDD remained stable throughout the postePEG-J
period (weeks 4e54), and was 1572 ± 566 mg at last visit, with
similar proportions of patients receiving dosing increases or de-
creases >50 mg and by similar magnitudes. The mean ± SD
morning levodopa dose of LCIG was 177 ± 68 mg (8.9 ± 3.4 mL of
LCIG). About 86% of patients required a morning dose <250 mg
(Table 1). The mean ± SD continuous LCIG dosage was 82 ± 33 mg/
h. About 85% of patients required a continuous dosage from 40 to
120 mg/h (Table 1). Patients self-administered a mean of
approximately 1 extra dose/day (mean 43 ± 20 mg per dose)
before visits at postePEG-J weeks 4 to 54. Starting at week 12 visit,
>40% of patients did not require extra doses the day prior to
scheduled visits.
LCIG was used as daytime monotherapy for the ﬁrst 4 weeks by
297/324 patients (92%; 8% required early reintroduction of anti-PD
medications, as determined by investigators and individually
approved by the medical monitor), 86% (236/276) of patients
received monotherapy at the end of the study (weeks 49e54), and
76% received monotherapy throughout treatment. The mostTable 1
LCIG dosesa in the open-label study (n ¼ 317).
Morning doseb n (%)
<50 mg 2 (<1)
50e<100 mg 31 (10)
100e<150 mg 79 (25)
150e<200 mg 80 (25)
200e<250 mg 81 (26)
250e<300 mg 23 (7)
300e<350 mg 16 (5)
350 mg 5 (2)
Continuous dose n (%)
<40 mg/h 17 (5)
40e<80 mg/h 149 (47)
80e<120 mg/h 119 (38)
120e<160 mg/h 24 (8)
160e<200 mg/h 5 (2)
200e<240 mg/h 3 (1)
LCIG, levodopa-carbidopa intestinal gel.
a 1 mL of LCIG contains 20 mg of levodopa.
b Morning dose does not include the additional 3 mL of LCIG needed to
compensate for the volume needed for tube priming (i.e. equivalent to 60 mg of
levodopa administered during the tube ﬂush that occurs after turning off the
pump).
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agonists (13%) and amantadine (10%).3.1.2. Double-blind trial
The titration scheme was constrained/limited by protocol
blinding, and LCIG replaced only the levodopa portion of patients'
prior/routine therapies (only 16% of patients received monotherapy
prior to randomization). Despite these limitations, which addition-
ally restricted how rapidly titration could proceed, dose optimiza-
tionwas achieved in a mean 7.1 ± 2.5 days for the LCIG arm (n¼ 37).
The mean levodopa TDD was higher versus baseline (Fig. 2B) e
increased for practically all patientsewith TDD of 1005 ± 374mg in
the LCIG arm at baseline, 1181 ± 480 mg after titration, and a
mean ± SD rescue dose of 140 ± 81 mg (LC-IR tablets).3.2. Efﬁcacy in each study
At 4 weeks post PEG-J (the ﬁrst assessment post-titration in
both studies), patients in the open-label monotherapy study had a
mean change from baseline (improvement) of 3.9 ± 3.1 h of “off”
time, which was similar to the mean change of 3.7 ± 2.5 h for the
LCIG arm in the double-blind adjunctive-therapy trial. “On” time
without troublesome dyskinesia increased (improved) by
4.3 ± 3.8 h in the open-label study and, in the double-blind study,
by 3.6 ± 3.4 h in the LCIG arm.
At 12 weeks (the double-blind trial's primary endpoint), mean
change in “off” time was similar between the open-label study
(3.9 ± 3.2 h; P < 0.001) and LCIG arm of the double-blind trial
(3.3 ± 3.1 h; Supplemental Fig. 1). The 12-week increase in “on”Table 2
Most common adverse events (reported by >5% of patients in any study arm) through th
Adverse event NJ period
Open-label (n ¼ 354)
n (%) of patients
Any adverse event 166 (46.9)
Any serious adverse event 6 (1.7)
Complication of device insertiona 26 (7.3)









Incision site erythema 1 (0.3)
Post-operative wound infection Not applicable
Orthostatic hypotension 7 (2.0)
Pneumoperitoneum Not applicable
Dyskinesia 2 (0.6)
Procedural site reaction 0
Dizziness 6 (1.7)
Dyspepsia 4 (1.1)




Confusional state 2 (0.6)
Hiatus hernia 3 (0.8)
Pyrexia 1 (0.3)
Atelectasis 1 (0.3)
Post-operative ileus 1 (0.3)
NJ, nasojejunal; PEG-J, percutaneous endoscopic gastrojejunostomy. Adverse events repo
a Events with this term were most often additionally coded to abdominal pain.time without troublesome dyskinesia also paralleled the change in
“off” time in the open-label study (4.5 ± 3.6 h; P < 0.001) and the
double-blind trial (3.3 ± 3.3 h for LCIG).
Discontinuations due to lack of efﬁcacy were rare, occurring in 2
patients in the open-label study (at days 77 and 91) and none of the
37 LCIG patients in the double-blind trial.3.3. Tolerability
3.3.1. NJ (Open-label study only)
Of 354 patients entering the NJ phase of the open-label study, 30
discontinued during the NJ phase due to withdrawal of consent (12
patients, reasons not collected), protocol violation (7 patients),
adverse event (AE; 5 patients), lack of efﬁcacy (5 patients; occurring
on days 5e8), or administrative reason (1 patient). Of 5 patients
discontinuing due to an AE, 2 reported AEs that investigators
deemed possibly related to treatment (dysphagia, vomiting, and
complication of device insertion during NJ placement in 1 patient
and hallucination in the other).
During the NJ phase, 166 patients (47%) experienced AEs; 91
patients (26%) experienced AEs possibly/probably related to treat-
ment. Overall, the most common AEs during the NJ phase were
insomnia (7.9%), complication of device insertion (7.3%), and
oropharyngeal pain (6.5%; Table 2). For these 3 AEs, all cases were of
mild-to-moderate severity except for 1 case of insomnia, whichwas
categorized as severe and resolved the following day. Serious AEs
were infrequent (1.7%: hepatic steatosis and syncope for 1 patient;
anemia, pneumonia, urinary tract infection, weight decreased, and
basal cell carcinoma for 1 patient each).e ﬁrst 4 weeks after PEG-J placement.
PEG-J weeks 1e4
Open-label (n ¼ 324) Double-blind LCIG arm (n ¼ 37)
n (%) of patients n (%) of patients
254 (78.4) 32 (86.5)
44 (13.6) 5 (13.5)
112 (34.6) 21 (56.8)
84 (25.9) 19 (51.4)
36 (11.1) 4 (10.8)
59 (18.2) 9 (24.3)
36 (11.1) 8 (21.6)
34 (10.5) 9 (24.3)
24 (7.4) 3 (8.1)
20 (6.2) 2 (5.4)
17 (5.2) 1 (2.7)
18 (5.6) 2 (5.4)
23 (7.1) 3 (8.1)
23 (7.1) 3 (8.1)
12 (3.7) 4 (10.8)
19 (5.9) 4 (10.8)
14 (4.3) 2 (5.4)
16 (4.9) 2 (5.4)
8 (2.5) 3 (8.1)
10 (3.1) 2 (5.4)
12 (3.7) 2 (5.4)
9 (2.8) 6 (16.2)
8 (2.5) 2 (5.4)
9 (2.8) 3 (8.1)
4 (1.2) 3 (8.1)
3 (0.9) 3 (8.1)
6 (1.9) 2 (5.4)
4 (1.2) 3 (8.1)
2 (0.6) 2 (5.4)
rted are treatment-emergent. A single event could be coded to 1 preferred term.
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monia (3.4% of patients) are of particular relevance to the NJ period.
Dysphagia and dyspnea were experienced by 3 patients each,
gastroesophageal reﬂux disease and pneumonia were experienced
by 2 each, and pyrexia and atelectasis were experienced by 1 each.
3.3.2. PEG-J (Open-label and double-blind studies)
The most common AEs during PEG-J weeks 1e4, as assessed for
the open-label study (n¼ 324) and in the LCIG arm of the direct-to-
PEG-J double-blind trial (n¼ 37), respectively, were complication of
device insertion (35% and 57%) and abdominal pain (26% and 51%)
(Table 2). In both studies, the most common AEs were associated
with the procedure or device and decreased substantially after
week 1. The types and incidence of AEs not associated with the
procedure or device were similar between the trials; discontinua-
tions for those AEs were similar between those receiving LCIG in
the open-label and double-blind studies (2.2% and 2.7%,
respectively).
Across the entire 54-week postePEG-J period of the open-label
study (n ¼ 324), the most common AEs typically occurred early in
the study (during the ﬁrst week). Overall, serious AEs were re-
ported in 105 (32%) patients, most often complication of device
insertion (6.5%), abdominal pain (3.1%), and peritonitis (2.8%) [14].
AEs leading to withdrawal occurred in 22 patients post PEG-J, and
the most common were complication of device insertion (6 pa-
tients), abdominal pain (3 patients), dyskinesia (2 patients), death
of unknown etiology (2 patients), and completed suicide (2 pa-
tients; both with a history of depression). Therewere 8 deaths, with
none considered related to the treatment system; 7were due to AEs
that occurred during the PEG-J phase (e.g. suicide in 2 patients;
cerebrovascular accident, cachexia, and multiple complications in 1
patient each) [14].
During the full 12-week, double-blind study, the most common
AEs generally reﬂected those occurring in the ﬁrst week. Overall,
serious AEs were generally similar between arms and were re-
ported in 5 (14%) patients in the LCIG arm, with the most common
being confusional state (n ¼ 2) [11]. Two (5.4%) of the 37 LCIG pa-
tients discontinued: psychosis and a protocol violation (difﬁculty
swallowing the oral capsules) for 1 (2.7%) patient each. There were
no deaths [11].
4. Discussion
The LCIG phase 3 program demonstrated that it is possible to
initiate and titrate LCIG as daytime monotherapy in advanced PD
(open-label trial) as well as adjunctive therapy with other anti-PD
medications (double-blind trial). Further, introduction of LCIG
directly via PEG-J, as permitted by current prescribing guidelines,
has been shown to be practical and effectivewhile avoiding another
procedure and NJ-speciﬁc AEs e as well as potential discontinua-
tionse in patients whomight otherwise beneﬁt from LCIG therapy.
The goal of titration in these studies was to optimize motor
function while minimizing motor ﬂuctuations and disabling dys-
kinesias. The dose-adjustment methodology in the open-label
study utilized ﬂexible titration during the ﬁrst 2 weeks of treat-
ment. In contrast, the double-blind trial employed a strict/dictated
titration methodology to maintain the treatment blind, which
restricted how rapidly titration could proceed. However, despite
these study differences, time to optimization of LCIG in the double-
blind study was comparable to that in the open-label study (means
of 7.1 and 7.6 days, respectively).
As expected, mean titrated LCIG dose post PEG-J was higher in
the open-label monotherapy study (1532 mg) than that of the
double-blind adjunctive trial (1181 mg); however, AEs during the
ﬁrst 4 weeks post PEG-J were generally similar between studies. Inboth studies, the mean post-titration TDD for LCIG (1572 mg and
1181 mg at last visit, respectively) was higher than that of oral
levodopa at screening (1083 mg and 1097 mg).
In the large open-label study, long-term data over more than a
year showed that mean TDD remained steady, patients achieved
and sustained a signiﬁcant improvement in “off” time, and use of
extra doses was minimal (a mean of ~1/day in weeks 4e54).
Morning and continuous doses typically fell into typical ranges:
86% of patients required a morning dose of <250 mg and 85%
required a continuous dosage of 40e120 mg/h. The on-treatment
mean TDD (1572 mg at last visit) was generally higher than the
mean levodopa TDD at screening (1083 mg), which reﬂected the
discontinuation of adjunctive medications. This increase is also
likely to be related to reduced plasma ﬂuctuation with LCIG treat-
ment, which permitted more precise targeting of plasma levels that
allowed somewhat higher doses while reducing ﬂuctuations that
exceed patients' narrow therapeutic windows.
A key ﬁnding in the open-label study was that although 80% of
patients had used adjunctive therapies at screening and adjunctive
therapy was permitted after the initial 4-week period, three quar-
ters of this advanced PD population received LCIG monotherapy
throughout the study. This study provided an example of how
complex anti-PD regimensmight be converted tomuch simpler but
potentially more effective LCIG monotherapy. Compared with
polypharmacy, LCIG monotherapy facilitates ease of dose adjust-
ments, when required, to address AEs or PD symptoms [13] and
avoids AEs associated with adjunctive medications that patients
may no longer need, such as dopamine agonists. In addition,
monotherapy simpliﬁes complicated treatment regimens, which
may improve adherence issues including overall compliance and
mistimed dosing, particularly in older patients [21,23e25]. In cases
where adjunctive treatments are needed (e.g. amantadine or
dopamine agonists), reintroduction can be achieved safely without
impacting efﬁcacy. Although AEs associated with long-term use of
levodopa-carbidopa were not fully evaluated in this study, long-
term AE data are being examined. Monotherapy may lead to
higher levodopa doses and increase the risk of known levodopa-
associated AEs, such as somnolence, compulsive behaviors,
depression, nausea, and neuropathy.
The double-blind trial is suggestive that an NJ period is not
necessarily required to initiate LCIG. Rather, treatment can begin
directly with the PEG-J procedure. This is of great importance
because it highlights that patients' motor outcomes may be com-
parable whether they receive direct PEG-J or temporary NJ place-
ment. NJ requires an additional procedure, and sedation and
hospitalization are associated with elevated risks for PD patients
[26]. Nonetheless, initiating LCIG via a temporary NJ tube might be
helpful in select patients to ensure that they can handle the treat-
ment system with a favorable response prior to permanent PEG-J.
Twelve of the 30 patients who discontinued the open-label
study during the NJ period withdrew consent and 5 discontinued
due to an AE. As levodopa-responsive PD was a key inclusion cri-
terion, withdrawal due to lack of efﬁcacy was uncommon in the NJ
(n ¼ 5, 1.4%) and PEG-J periods (n ¼ 2, 0.6%) of the open-label study
and did not occur in the LCIG arm of the double-blind trial. The
pivotal placebo-controlled trial suggests that careful evaluation of a
patient's response to oral levodopa is indicative of response to LCIG.
Thus, evaluation of direct-to-PEG-J titration versus an initial NJ
phase for individual patients should carefully consider factors
including the potential advantages and disadvantages of NJ-tube
placement, including tolerance for the NJ procedure and beneﬁt-
risk to the patient.
This review has several limitations, primarily that no direct
comparative analyses of these 2 unique trials can be performed.
LCIG was assessed as ﬂexibly dosed monotherapy via NJ and PEG-J
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doses via only PEG-J in a double-blind study. The number of pa-
tients and long duration of the open-label study, when compared
with previously published literature, lend credibility to the dosing
results. The smaller sample size and shorter duration of the
placebo-controlled trial limits interpretation; however, its double-
blind, double-dummy design is a key strength. Ideally, the use of
direct-to-PEG-J titration versus temporary NJ placement should be
evaluated prospectively in a single study; similarly, LCIG mono-
therapy should be evaluated against LCIG treatment with adjunc-
tive anti-PD medication in both the short and long term.
Clinical trial data illustrate that dose optimizationwith LCIG can
be achieved within several days for most patients. Similar re-
ductions in “off” time have been shownwhether LCIG was initiated
as monotherapy or with ongoing adjunctive anti-PD medications.
The rates of discontinuation attributed to AEs that were not pro-
cedure/device associated was also similar when LCIG was used as
monotherapy or polypharmacy. In practice, monotherapy may
facilitate dose adjustments and simplify compliance.
Further, these studies demonstrate that it is feasible to initiate
LCIG directly via PEG-J without an initial NJ period, although the
results may not be generalizable across the advanced PD popula-
tion due to variability in individual patient characteristics, such as
disease severity and fragility. As the NJ titration period was asso-
ciated with additional complications (e.g. AEs of insomnia and
oropharyngeal pain) and requires another procedure for placement
under anesthesia, these data support the safety and efﬁcacy of
considering a direct-to-PEG-J initiation. While a subgroup of pa-
tients who have failed other therapies or remain difﬁcult to treat
may need the NJ tube, NJ placement may be best viewed as an
optional procedure after a careful discussion of its potential risks
and beneﬁts in select patients.
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